⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

January 1, 2016MedChemComm

Discovery and optimisation of potent and highly subtype selective Na v 1.8 inhibitors with reduced cardiovascular liabilities

Sharan K. Bagal Mark I. Kemp Peter J. Bungay Tanya Hay Yoshihisa Murata C. Elizabeth Payne Edward B. Stevens Alan D. Brown David C. Blakemore Matthew S. Corbett Duncan C. Miller Kiyoyuki Omoto Joseph S. Warmus

View at Publisher

Ask AI

Bookmark

Share

Ask about this paper

Answers are grounded in this paper and cite their sources.

Ask your own question…

Abstract

Potent and subtype selective Na v 1.8 inhibitors were designed and optimised for selectivity over hERG ion channel inhibition.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Bagal et al. (2016) studied this question.

synapsesocial.com/papers/6a829248ca0a238f9c75a6d4 https://doi.org/10.1039/c6md00281a

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Discovery of Clinical Candidate 4-[2-(5-Amino-1<i>H</i>-pyrazol-4-yl)-4-chlorophenoxy]-5-chloro-2-fluoro-<i>N</i>-1,3-thiazol-4-ylbenzenesulfonamide (PF-05089771): Design and Optimization of Diaryl Ether Aryl Sulfonamides as Selective Inhibitors of Na<sub>V</sub>1.7preclinical · 2017 · 89 citations
2Discovery of Arylsulfonamide Na v 1.7 Inhibitors: IVIVC, MPO Methods, and Optimization of Selectivity Profilepreclinical · 2021 · 13 citations
3Mechanism-specific assay design facilitates the discovery of Nav1.7-selective inhibitorspreclinical · 2018 · 34 citations
4Cryo-EM reveals an unprecedented binding site for NaV1.7 inhibitors enabling rational design of potent hybrid inhibitorspreclinical · 2023 · 32 citations
5New Diarylamine KV10.1 Inhibitors and Their Anticancer Potentialpreclinical · 2022 · 10 citations

Ligand-based pharmacophore modeling for the discovery of NaV1.7 inhibitors2026
Potent <i>N</i>-(1,3-Thiazol-2-yl)pyridin-2-amine Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors with Excellent Pharmacokinetics and Low Affinity for the hERG Ion Channel2004
Novel 1-Phenyl-2,3-dihydroquinazolin-4(1H)-one Derivatives as Na <sub>v</sub> 1.8 Voltage-Gated Sodium Channels Inhibitors2026
Synthesis, conformational preferences, and biological activity of conformational analogues of the microtubule-stabilizing agents, (−)-zampanolide and (−)-dactylolideMedChemComm · 2019
Selective in vitro anti-cancer activity of non-alkylating minor groove bindersMedChemComm · 2019

More from MedChemComm

More from Pfizer (United States)

More from Pfizer (United Kingdom)

More from General Dynamics (United States)

More from Foton Motors (China)